Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill Gilbert

Showing results (21-30 of 78) with videos related to

Pageof 8
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 27, 2016
Neurocognitive function in patients with head and neck cancer undergoing primary or adjuvant chemoradiation treatmentStewart M Bond, Mary S Dietrich, Jill Gilbert, et al.
Head & Neck|February 14, 2006
Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology GroupJill Gilbert, Yi Li, Harlan A Pinto, et al.
Head & Neck|May 24, 2011
Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter geneJill Gilbert, Kirsten L Haman, Mary S Dietrich, et al.
Cancer Treatment Reviews|April 29, 2018
Management of treatment-related toxicities in advanced medullary thyroid cancerMarcia S Brose, Keith C Bible, Laura Q M Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2013
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trialAthanassios Argiris, Musie Ghebremichael, Jill Gilbert, et al.
Cancer|March 19, 2016
Using the galactose-α-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximabJared Weiss, Juneko Grilley Olson, Allison Mary Deal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignanciesMichelle A Rudek, Ming Zhao, Ping He, et al.
The Journal of Experimental Medicine|September 28, 2005
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinomaPaulo C Rodriguez, Claudia P Hernandez, David Quiceno, et al.
Head & Neck|August 10, 2020
Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiationDerek K Smith, Anthony Cmelak, Ken Niermann, et al.
Head & Neck|July 14, 2012
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology GroupJill Gilbert, Ju Whei Lee, Athanassios Argiris, et al.
Pageof 8

Showing results (21-30 of 78) with videos related to

Sort By:
Pageof 8
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 27, 2016
Neurocognitive function in patients with head and neck cancer undergoing primary or adjuvant chemoradiation treatmentStewart M Bond, Mary S Dietrich, Jill Gilbert, et al.
Head & Neck|February 14, 2006
Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology GroupJill Gilbert, Yi Li, Harlan A Pinto, et al.
Head & Neck|May 24, 2011
Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter geneJill Gilbert, Kirsten L Haman, Mary S Dietrich, et al.
Cancer Treatment Reviews|April 29, 2018
Management of treatment-related toxicities in advanced medullary thyroid cancerMarcia S Brose, Keith C Bible, Laura Q M Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2013
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trialAthanassios Argiris, Musie Ghebremichael, Jill Gilbert, et al.
Cancer|March 19, 2016
Using the galactose-α-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximabJared Weiss, Juneko Grilley Olson, Allison Mary Deal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignanciesMichelle A Rudek, Ming Zhao, Ping He, et al.
The Journal of Experimental Medicine|September 28, 2005
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinomaPaulo C Rodriguez, Claudia P Hernandez, David Quiceno, et al.
Head & Neck|August 10, 2020
Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiationDerek K Smith, Anthony Cmelak, Ken Niermann, et al.
Head & Neck|July 14, 2012
Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology GroupJill Gilbert, Ju Whei Lee, Athanassios Argiris, et al.
Pageof 8